Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03639168
Other study ID # CC-HN-1
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date June 6, 2018
Est. completion date June 2, 2021

Study information

Verified date August 2021
Source Fudan University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators conducted this study to evaluate the efficacy of Chidamide combined with cisplatin in recurrent or metastatic head and neck adenoid cystic carcinoma.


Description:

Adenoid cystic carcinomas (ACCs) constitute of 1% of head and neck cancers. This type of tumor grows slowly with a high potential of local recurrence. Approximately 50% of patients develop distant metastases, and 33% patients die within 2 years. The initial therapy of these malignancies consists of surgical resection followed by radiotherapy. Systemic therapy is crucial in the management of recurrent and metastatic disease. However, nowadays, there were no standard chemoimmunotherapy regimes. Previous report showed that overall response rate was only less than 10% using single-agent chemotherapies, and the best results were achieved by cisplatin. Chidamide is a new benzamide class of histone deacetylase inhibitor with marked antitumor activity. And a phase I study has showed that one of three patients with submandibular adenoid cystic carcinoma achieved a partial response treated with Chidamide. The investigators conducted this study to evaluate the efficacy of Chidamide combined with cisplatin in recurrent or metastatic head and neck adenoid cystic carcinoma, in order to find a potential promising way to treat this kind of disease.


Recruitment information / eligibility

Status Completed
Enrollment 22
Est. completion date June 2, 2021
Est. primary completion date June 24, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Age range 18-75 years old 2. Histological confirmed recurrent or metastatic head and neck adenoid cystic carcinoma 3. Unable to treat with surgery/radiotherapy, or previously failure to non-cisplatin systematic treatment; 4. Eastern Cooperative Oncology Group performance status 0 to 2; 5. Patients have written informed consent to participate in the study; 6. anticipated to live ?3 months; 7. Absolute neutrophil count = 1.5×109/L,platelet = 100×109/L,hemoglobin = 90 g/L 8. total bilirubin < 1.5×upper limit of normal(ULN), ALT and AST < 3× ULN 9. serum creatine <1.5×ULN, and creatinine clearance rate (CCR) = 50 ml/min 10. Ultrasonic cardiogram showed left ventricle ejection fraction = 50%, EKG showed no signs of myocardial ischemia, with no previous arrhythmia which need pharmacological intervention. 11. Measurable disease was defined as at least one lesion =1.5 cm in length-diameter and =0.5 cm in short-diameter by CT. Exclusion Criteria: 1. Previously treated with HDACi; 2. Treated with cisplatin-contained regimes in the past half of the year, and not achieving PR/CR; 3. History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix; 4. HIV, HCV, or syphilis infection; 5. Pregnant or lactating women; 6. Serious uncontrolled infection; 7. Severe neurol of mental illness, including dementia and epilepsy; 8. Having contraindications to the use of oral medication, such as unable to swallow, nausea and vomiting, chronic diarrhea or suffering from a bowel obstruction; 9. Participated in other clinical trials in 4 weeks; 10. Other coexisting diseases or situations that may cause patients to fail to complete clinical trials; 11. History of QTc interval prolongation (Male >450ms,Female >470ms), ventricular tachycardia, auricular fibrillation, heart block of more than II degrees, myocardial infarction in 1 year, congenital heart disease, with symptomatic coronary heart disease requiring medication.

Study Design


Intervention

Drug:
Chidamide combined with cisplatin
Chidamide combined with cisplatin

Locations

Country Name City State
China Kai Xue Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Serum ctDNA biomarker relationship between biomarker and treatment outcome throughout the treatment period,up to 6 months
Primary Overall response rate (ORR) Defined as numbers of patients achieved complete response and patial response of treatment 6 weeks
Secondary Disease control rate (DCR) Defined as numbers of patients achieved complete response, patial response, and stable disease of treatment 6 weeks
Secondary Progression-free survival (PFS) Defined as the time from randomization until objective tumor progression or death 6 weeks
Secondary Scoring of quality of life: EORTC-QLQ-30 Quality of life was evaluated using EORTC-QLQ-30. All subscales are summed to compute a total score, and total scores are recorded. Lower scores represent a better outcome. 6 weeks
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05030077 - Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma Phase 2
Recruiting NCT04848454 - Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy Phase 2
Completed NCT03079427 - Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma Phase 2
Recruiting NCT03919552 - Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma Phase 3
Not yet recruiting NCT01285674 - Intratympanic Steroid Treatment For The Prevention Of Inner Ear Toxicity Associated With Systemic Treatment With Cisplatin. N/A
Recruiting NCT05244577 - Olanzapine Combined With Fosaprepitant, Ondansetron, and Dexamethasone for Preventing Nausea and Vomiting in Patients With Testicular Cancer Phase 3
Recruiting NCT03373019 - Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Phase 2